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tendon cells in vitro is reduced by
glucocorticoids
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Abstract
Background: The use of corticosteroids (e.g., dexamethasone) as treatment for tendinopathy has recently been
questioned as higher risks for ruptures have been observed clinically. In vitro studies have reported that
dexamethasone exposed tendon cells, tenocytes, show reduced cell viability and collagen production. Little is
known about the effect of dexamethasone on the characteristics of tenocytes. Furthermore, there are uncertainties
about the existence of apoptosis and if the reduction of collagen affects all collagen subtypes.
Methods: We evaluated these aspects by exposing primary tendon cells to dexamethasone (Dex) in concentrations
ranging from 1 to 1000 nM. Gene expression of the specific tenocyte markers scleraxis (Scx) and tenomodulin
(Tnmd) and markers for other mesenchymal lineages, such as bone (Alpl, Ocn), cartilage (Acan, Sox9) and fat (Cebpα,
Pparg) was measured via qPCR. Cell viability and proliferation was calculated using a MTS Assay. Cell death was
measured by LDH assay and cleaved caspase-3 using Western Blot. Gene expression of collagen subtypes Col1, Col3
and Col14 was analyzed using qPCR.
Results: Stimulation with Dex decreased cell viability and LDH levels. Dex also induced a significant reduction of
Scx gene expression and a marked loss of fibroblast like cell shape. The mRNA for all examined collagen subtypes
was found to be down-regulated. Among non-tendinous genes only Pparg was significantly increased, whereas
Acan, Alpl and Sox9 were reduced.
Conclusions: These results indicate a Dex induced phenotype drift of the tenocytes by reducing scleraxis
expression. Reduction of several collagen subtypes, but not cell death, seems to be a feature of Dex induced tissue
degeneration.
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Background
Chronic tendon pain (tendinopathy) is a troublesome
condition that often affects professional and recreational
athletes but can also be found among non-active individ-
uals [1–3]. The histopathological features (tendinosis)
are mainly defined as structural degeneration character-
ized by reduced levels of type 1 collagen and haphaz-
ardly increased proliferation of smaller type 3 collagen
and increased vascularization [4, 5]. Furthermore, cell
proliferation and change in cell shape towards rounded
and wavy cells, but also occasional cell death has been
reported [4, 5]. In addition, it has been shown that in
some areas of the tendon features of lipoid degeneration
can occur [4]. Furthermore, adherence of fat rich peri-
tendinous tissues onto the tendon proper has been
observed [6, 7]. Calcification is another feature that is
frequently present potentially being driven by an abnor-
mal pathway of tendon healing [4, 8]. In areas with high
levels of compressive loads fibrocartilaginous metaplasia
has been observed [4, 9]. The mechanisms behind the
tissue changes are not fully understood. However, there
is some evidence that extensive load and the imbalance
of molecules such as hormones and neuropeptides are
involved [9–11].
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Treatment methods for tendinopathies are often
applied with low scientific evidence [12] and there are
controversies about the use of some of them. Especially
the application of glucocorticoids, e.g., the commonly
used substance dexamethasone (Dex), is still heavily de-
bated and questioned. Glucocorticoids in general are
accepted as effective treatments for many inflammatory
conditions [13]. For many years tendinopathies were
considered as non-inflammatory and degenerative condi-
tion (“tendinosis”) by several authors as no signs of a
classical inflammation was found in the tendon proper
[14, 15]. However, recent studies using advances tech-
niques have suggested that tendon degeneration may be
an active process with involvement of aspects of
inflammation-mediated responses especially in the early
stages [16–18]. Clinical studies on the use of glucocorti-
coids for tendinopathies have reported short-term pain
relief but poor long-term effects including a weakening
of tendon structure on the longer perspective [19, 20].
In fact, many reports about spontaneous, often non-
traumatic tendon ruptures following the use of these
substances have been published [21–28].
In vitro studies have shown that exposure to gluco-
corticoids has negative effects on tendon cells [29]. It
can lead to a reduction in cell viability, proliferation
and reduced production of total collagen particularly
collagen 1, and proteoglycans [30–35]. These effects
are thought to weaken the tendon structure indicated
by decreased mechanical properties [29, 36] and may
eventually lead to higher risks for tendon ruptures.
Conflicting data are available on whether apoptosis is
a feature involved in this process [32, 37, 38]. Fur-
thermore it is unclear if all collagen subtypes are
affected by dexamethasone in the same way or if it is
restricted to the collagen I subtype. As tendinopathy
is indicated by an increased collagen 3 production [5]
it is important to know how the expression of this
subtype responds to glucocorticoids. The effect on
collagen type 14, often found in areas of high mech-
anical stress [39, 40], needs to be evaluated as well.
Recently it has been reported that dexamethasone can
influence the differentiation of tendon stem cells in vitro
and that it thus can have an impact on the phenotype of
cells towards non-tendinous like cells [41–43]. However,
no attention has been paid on the potential effect on the
expression of tendon specific markers in differentiated
primary tendon cells, tenocytes. This is a drawback since
this cell population makes up the vast majority of cells
in the tendon. The primary purpose of this study was
therefore to analyze the expression of tenocyte specific
markers scleraxis and tenomodulin in response to Dexa-
methasone stimulation. Furthermore, the effect on the
occurrence of cell death and the expression of collagen
subtypes 1, 3 and 14 were evaluated.
Methods
Material and cell culture
Tendon cells used in the present study were derived
from plantaris tendon samples from patients (n = 7; 5
men, 2 women; mean age 46 years) with chronic co-
existing midportion Achilles and plantaris tendinopathy
[44]. All patients had pain duration of at least 3 months
and verified tendinopathies as shown by clinical examin-
ation including Ultrasound and Colour Doppler (US/CD).
Exclusion criteria were acute and chronic inflammatory
diseases, previous intratendinous treatments and partial
tears in the Achilles tendon.
The tissue was obtained in the course of a previously
described surgical procedure that includes plantaris
tendon removal and Achilles tendon scraping [7, 45]. The
isolation and culturing of primary tendon cells was carried
out according to a protocol that has been routinely used
in our laboratory [46]. Cells were cultured in DMEM sup-
plemented with 10 % fetal bovine serum (FBS; Invitrogen,
code: 16000), 1 % pen-strep (Invitrogen; code: 15140) and
0.2 % L-glutamine (Invitrogen; code: 25030) at 37 °C in a
humidified atmosphere of 5 % CO2.
The cells in this study were used in passages 2–4. Prior
to stimulation with dexamethasone cells were serum-
starved for 24 h with 1 % FBS in DMEM. All experiments
(see below) were performed at least three times and cells
from at least two different patients were used.
Ethical considerations
The principles expressed in the Declaration of Helsinki
were followed. A written informed consent was received
from all patients included in this study. Ethical approvals
were obtained from the Ethical Committee at the Med-
ical Faculty of Umeå University, and the Regional Ethical
Review Board in Umeå (dnr 04-157 M; 2011-83-32 M).
Immunocytochemistry
In order to characterize the primary tendon cells in vitro
immunocytochemistry (ICC) was performed. Antibodies
were directed towards hematopoietic progenitor cell anti-
gen CD34 (1:25; Santa Cruz; code: sc9095), collagen 1
(COL1) (1:50; Abcam; code: ab34710), collagen 3 (COL3)
(1:50; Abcam; code: ab7778), octamer-binding transcrip-
tion factor 4 (OCT4) (1:50; Abcam; code: ab27985),
scleraxis (SCX) 1:50; Abcam; code: ab58655), tenomodulin
(TMD) 1:50; Abcam; code: ab203676).
For the procedure 15,000 cells/well were seeded on 8-
well chamber slides overnight. The following day cells
were initially fixed in 3.7 % paraformaldehyde in 1× PBS
for 15 min. Then they were washed 4 times for 1 min in
1× PBS. After that cells were blocked with normal serum
(1:20 in 1× PBS) for 15 min and incubated with the
primary antibody for 60 min at 37 °C. Subsequently they
were washed and blocked again, and incubated with the
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secondary antibody for 30 min at 37 °C. Eventually
another washing step was performed before the slides
were mounted using ProLong® Diamond Antifade Mount-
ant with DAPI (Life Technologies; code: P36962). In order
to evaluate the specificity of the immunofluorescence a
control staining, where the primary antibody was replaced
with 1× PBS, was performed. The immunoreactions were
analyzed via a Zeiss Axioskop 2 plus microscope equipped
with epifluorescence and an Olympus DP70 digital
camera. The figure montages were created with Photo-
shop CS5 Extended software.
When using primary antibodies from rabbits, swine
normal serum (1:20; Jackson I.R; code: 014-000-121) was
used for blocking and swine anti-rabbit secondary anti-
body conjugated with tetramethylrhodamine isocyanate
(TRITC) (1:40; DAKO; code: R0156) was applied. For
goat antibodies, donkey normal serum (1:20; Jackson I.R;
code: 017-000-121) and donkey anti goat secondary anti-
body conjugated with fluorescein isothiocyanate (FITC)
(1:50; Jackson I.R.; code: 705-095-147) were used.
Stimulation with dexamethasone (Dex)
Dexamethasone (Sigma; code: D4902) was solved in pure
ethanol and diluted into concentrations of 1 mM,
10 mM, 100 mM and 1000 mM. For exposure the Dex
solutions were applied 1:1000 in 1 % FBS in DMEM
(2 μl Dex + 2 ml 1 % FBS in DMEM). Thus the final con-
centrations of Dex were 1 nM, 10 nM, 100 nM and 1000
nM. The durations of stimulation (time points) were 6 h,
12 h, 24 h, 48 h, 72 h, 96 h and 120 h. The control, un-
stimulated cells, were exposed to pure ethanol using the
same volume (2 μl ethanol + 2 ml 1 % FBS in DMEM).
Measuring cell death (LDH assay)
Cell death in response to the Dex exposure was mea-
sured by a lactate dehydrogenase (LDH) assay from
Promega (code: G1780). At each time point supernatant
was collected and then immediately stored at -20 °C. For
the analysis 50 μl of supernatant was pipetted into a 96-
well plate, then mixed with 50 μl reconstituted substrate
mix and incubated for 30 min in a light protected envir-
onment under shaking. After that 50 μl of stop solution
was applied and the absorbance was read at 490 nm
using a plate reader. LDH was measured at all time
points and all concentrations described above.
Measuring cell viability (MTS assay)
The effect of dexamethasone on the proliferation and
viability of tendon cells was measured using a MTS
assay (CellTiter 96® Aqueous One Solution Cell Prolifer-
ation Assay; code: G3581). For this purpose tendon cells
were seeded in a 96 well plate overnight at a density of
5,000/well. For analysis MTS reagent (20 μl per 100 μl
media) was added and incubated for 4 h at 37 °C, 5 %
CO2. The amount of formazan produced by cellular
reduction of MTS, was measured with a micro-plate
reader and the absorbance of 490 nm. MTS was
measured at all time points and all concentrations
described above.
RNA isolation, reverse transcription, and qPCR
For analyzing gene expression qPCR was performed.
Genes related to collagens (Col1, Col3, Col14) were
analyzed. Furthermore markers that are tenocyte specific
(Scx, Tnmd) and those characterizing non-tendinous
cells (bone: Alpl, Ocn; cartilage: Acan, Sox9; fat: Pparg,
Cebpα) were looked at. All applied probes and primers
are listed in Tables 1 and 2.
Initially, RNA was isolated using an extraction kit
(Qiagen; code: 74106). The extracted RNA was then re-
verse transcribed into cDNA via a High Capacity cDNA
Reverse Transcription kit (Applied Biosystems; code:
4368813). The settings for the conversion which was
performed on a thermal cycler (Eppendorf Mastercycler
EP Gradient S) were as follow: 10 min at 25 °C, 120 min
at 37 °C, 5 min at 85 °C.
For the quantitative PCR (qPCR) either TaqMan fast
universal PCR mastermix (Applied Biosystems; code:
4352042) or SYBR Green fast universal PCR mastermix
(Applied Biosystems; code: 4385612) was used. For each
of the amplifications, 40 ng of cDNA was taken and
analyzed in technical dublicates.
The amplification was performed in a ViiA7 Real-Time
PCR system (Applied Biosystems). The expression levels of
genes were calculated in relation to the endogenous con-
trol β-actin (Actb) for the Taqman probes and Gapdh when
using SYBR Green. For more practical details see [46, 47].
mRNA was analyzed after stimulation with 100 nM Dex
after 12 h, 24 h, 48 h and 72 h. For Scx and Tnmd all
concentrations (1nM, 10nM, 100nM, 1000nM) were used.
Western blot
Cells were washed in sterile 1× PBS and then stored
in -80 °C until all time point were collected. On the
day of analyses cells were scraped in lysis buffer
(RIPA) supplemented with protease inhibitor (1:200),
Table 1 Probes used for qPCR (Taqman; Applied Biosystems)
Gene Amplicon length Code
Actb β-actin 63 Hs01060665_g1
Col1 Collagen type 1 66 Hs00164004_m1
Col3 Collagen type 3 65 Hs00943809_m1
Scx Scleraxis 63 Hs03054634_g1
Acan Aggrecan 91 Hs00153936_m1
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put in an Eppendorf tube, vortexed and then incubated on
ice for 30–60 min. After that the tubes were centrifuged
to remove the cell debris. The supernatant was taken and
analyzed for concentrations of total proteins using Protein
Assay Dye Reagent Concentrate (Bio-Rad; code: 500–
0006). Bovine Albumin Serum (BSA; Sigma; code: A9647)
was used as a standard. Before loading onto a SDS-PAGE
gel, in similar protein concentrations, the samples were
boiled in 2× Lammeli buffer (Bio-Rad; code: 161–0737)
supplemented with beta-mercaptoethanol. After the run
(150 V) the proteins were transferred to a polyvinylidene
fluoride transfer membrane for 1 h at 100 V. The mem-
brane was then blocked with either 5 % BSA or 5 % non-
fat milk powder in 1× TBS-T for 60 min and eventually
incubated with the primary antibody at 4 °C overnight.
Next day the membrane was washed in TBS-T (3×5 min)
and after that incubated with the secondary antibody at
room temperature for 60 min. After the final wash the
membranes were treated with chemiluminescent HRP
substrate (GE Healthcare; code: RPN2232) for 5 min and
then visualized using Odyssey® Fc imaging system (LI-
COR, Lincoln, NE, USA).
Antibodies were directed towards cleaved caspase 3
(cCasp3) (Cell Signaling; code: 9664), COL 1 (Cell Sig-
naling; code: 9496), SCX (Abcam; code: ab58655) and
TMND (Abcam; code: ab203676). Stimulation with Dex
was performed in a concentration of 100 nM for 12 h,
24 h, 48 h and 72 h.
Oil Red O staining
For the detection of adipocytes Oil Red O staining was
performed. Before that cells were stimulated with Dex
every second day for 21 days and media containing Dex
(100 nM) was replaced every second day.
Cells were initially fixed in 3.7 % paraformaldehyde for
30–40 min. After that they were washed with 1× PBS (3x5
min) and rinsed in water twice. After that Oil Red O Solu-
tion was applied for 50 min. Cells were then washed with
water and eventually stained with hematoxylin (10 min).
Statistical analysis
Data were statistically analyzed by using PASW Statistics
18 (SPSS). One-way analysis of variance (ANOVA),
followed by the Bonferroni post-hoc test, and independ-
ent t-tests were used. All results were successfully repro-
duced at least twice and performed in triplicates and
technical duplicates. Significance levels were predeter-
mined at p < 0.05.
Results
Primary tendon cells express tenocyte markers
The primary cells revealed immunoreactions for COL 1,
SCX, TNMD and to some extent COL 3 (Fig. 1a-d). No,
or very little, reactions were seen for stemness marker
OCT4 and endothelial marker CD34 (Fig. 1e, f ).
Decrease of cell death, cell viability and proliferation
The exposure of Dex leads to a dose-depended reduction
of cell viability after 72 h (Fig. 2a). Similar trends could
be observed also at earlier time point (not shown).
The LDH assay showed a dose-depended reduction of
cell death after 72 h (Fig. 2b) with similar trends for
earlier time points. There was no presence of cleaved
caspase-3 (not shown) after 24 h. The reduced number
of cells is also seen macroscopically (Fig. 2c).
Decreased Scx gene expression after Dex treatment
The expression of scleraxis (Scx) mRNA was reduced
(Fig. 3a, b) after Dex treatment at all time points exam-
ined, most prominently after 24 h. Gene expression for
Tnmd was very low and not considered for analysis.
Effects of Dex on tendon cell (tenocyte) phenotype
Among the analyzed non-tenocyte genes, only the fat
marker Pparg was significantly up-regulated on mRNA
level after Dex treatment (Fig. 3c). However, Oil red O
staining after 21 days of stimulation did not show any
presence of adipocytes in the culture (not shown).
Acan, Sox9 and Alpl were found to be decreased
(Fig. 3). The gene expression of Ocn and Cebpα was very
low in both groups.
Stimulated cells exhibited a different shape than un-
treated cells. They lost their typical elongated fibroblas-
tic appearance (Fig. 2c).
Decreased expression of collagens
Dex stimulation resulted in decreased expression of
Col1, Col3 and Col14 on mRNA level after 24 h (Fig. 4a),






Col1 Collagen type 1 F: CGATGGATTCCAGTTCGAGTAT
R: CATCGACAGTGACGCTGTAGG






Ocn Osteocalcin F: GACACCATGAGGACCCTCTC
R: GCCTGGTAGTTGTTGTGAGC
Scx Scleraxis F: CGAGAACACCCAGCCCAAAC
R: CTCCGAATCGCAGTCTTTCTGTC
Sox9 SRY-box 9 F: GGCGGAGGAAGTCGGTGAAGAA
R: GCTCATGCCGGAGGAGGAGTGT
Tnmd Tenomodulin F: TGGGTGGTCCCTCAAGTGAAAGT
R: CTCGACGGCAGTAAATACAACAATA
Spang et al. BMC Musculoskeletal Disorders  (2016) 17:467 Page 4 of 9
and similar results for other examined time points (24 h,
48 h, 72 h, 96 h). COL 1 was found to be reduced on
protein level as well (Fig. 4b).
Discussion
This is to our knowledge the first study evaluating teno-
cyte marker expression in response to exposure of the
corticosteroid Dexamethasone (Dex) in primary tendon
cells. Our results suggest that Dex leads to a marked
reduction of scleraxis, a transcription factor that has
been reported to be essential for tendon development
and differentiation [48]. At the same time we found that
the tendon cells lost their typical fibroblastic shape
during the stimulation. This indicates a potential pheno-
type change of the tenocytes as a result of Dex. When
evaluating the expression of non-tendinous markers, we
found that the adipocyte marker PPARG was up-
regulated. However, staining for adipocytes did not show
a presence of adipocytes within 21 days of stimulation.
That is not very surprising since studies have shown that
compared to tendon stem cells, primary cells have a very
low potential to differentiated into cartilage-, fat- and
bone related cells [49]. Studies on tendon stem cells
have reported a phenotype change towards fat cells via
reduction of scleraxis [41–43]. However, clone formation
experiments prior to the present study have indicated
that the cells in culture in the present study are mature
tendon cells and that the amount of possible stem cells
was very little. Thus, at least the marked reduction of
scleraxis must be related to changes occurring in primary
matured tendon cells. In fact, not all processes of teno-
cytes differentiation are fully understood yet. Therefore,
the reduction of scleraxis accompanied with the change in
cell shape in response to Dex could be a sign of reduced
tenocyte phenotype, which may potentially affect the
tendon. More studies are needed on how this scleraxis
reduction affects the cell on a downstream direction.
Another observation of this study is a decrease in cell
viability. This has been reported by other studies before
[30–32]. Surprisingly, this reduction was not associated
with an increase of cell death, as indicated by the reduc-
tion of LDH levels in our study. Furthermore, we did not
find cleaved caspase-3 by Western Blot. This may indicate
that apoptosis/necrosis is not a feature of Dex exposure as
previously reported by Wong et al. on primary patellar
tendon cells [32]. In fact, there are conflicting data in the
literature [32, 37, 38]. These discrepancies might be
explained by different concentrations of Dex and the use
Fig. 1 Primary tendon cells stained for COL 1 (a), COL 3 (b), TNMD (c), SCX (d), OCT4 (e) and CD34 (f). Immunoreactions are seen for COL1, COL3
(arrows), TNMD and SCX (arrows). No or very little reactions can be seen for OCT4 and CD34
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of cells from different tendons in these studies. In our
study, we did not find any signs of increased cell death
processes in cells derived from plantaris tendinopathy
tendons, with different concentrations (1 nM-1000 nM) of
Dex treatment within 5 days. However, it should also be
mentioned that LDH does not necessarily detect apop-
tosis. Necrotic processes are even more likely to be
detected since it measures plasma permeability. Based on
our results, it rather seems that the turnover in general,
i.e., both proliferation and cell death (necrosis/apoptosis),
is lower in stimulated cells as both cell viability and cell
death is decreased. That doesn’t mean that there is a
general decrease in cell death as these results are not
normalized. In fact, Poulsen and co-workers have sug-
gested that glucocorticoids can cause senescence in ten-
don cells, which can explain the reduced cell viability [50].
It is also known that patients with Cushing syndrome
(CS) resulting from chronic exposure to excessive circulat-
ing levels of glucocorticoids have major alterations in the
tendon structure and/or tendon function [51]. Despite
based on only a few studies, it shows that chronic use of
glucocorticoids harms the tendon even if used systemically.
The third finding of the present work was that Dex
not only reduced the expression of collagen 1 but also
mRNA of collagen 3 and 14. Previous studies have
shown that collagen 1, the main collagen in tendons, is
reduced after exposure to corticosteroids [30]. Collagen
3, a smaller collagen, is another collagen type in tendons
and known to be up-regulated in the process of tendino-
pathy [5]. Also collagen 14 is present in tendons [39].
Type 14 collagen is often found in areas of high mech-
anical stress [40]. The reduction of all examined collagen
subtypes indicates that Dex may lead to a weakening of
tendon structure. It is therefore not surprising that
spontaneous ruptures have been linked to injections of
corticosteroids in tendons [21–28]. Our results give a
plausible molecular explanation for that.
A drawback of this study is that it is unclear if the Dex
concentrations used in vitro are representative for the in
vivo situation in the tendon when it is clinically used.
However, we applied a wide range of concentrations and
stack to those used in previous studies. Another issue is
that most mRNA and protein analyses were solely
performed after 100nM Dex exposure. The effect of
Fig. 2 Effects of Dex on cell viability (MTS) and cell death (LDH) levels. A significant reduction in cell viability (a) and LDH (b) after 72 h of Dex
treatment is found. Microscopic pictures of stimulated cells (7 days) stained with Oil Red solution and hematoxylin show lower cell numbers and
a loss of fibroblastic appearance after treatment with Dex (c). *** p < 0.001
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Fig. 3 Results of Dex (100 nM) exposure on the relative Scx gene expression and the expression of non-tendinous genes. A significant down
regulation of Scx mRNA is seen (a) and this down regulation is consistent over a 48 h time course (b). Acan, Sox9 and Alpl expression is reduced
(c) and Pparg is up-regulated in cells exposed to Dex. *p < 0.05; ** p < 0.01; *** p < 0.001; n.s. (non-significant)
Fig. 4 Results of Dex (100 nM) exposure on the expression of collagens. mRNA of collagen subtypes Col 1, Col 3 and Col 14 is significantly
down-regulated after 24 h of Dex exposure (a) . COL 1 protein is decreased after 24 h and 48 h of Dex exposure (b). * p < 0.05; *** p < 0.001
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other concentrations was only measured for MTS and
LDH. We had tested other concentrations prior to these
experiments. Based on the results of these and the fact
that 100nM Dex had the highest impact on cell viability
we decided to use it for further experiments.
Conclusion
Overall, the results of our study suggest that Dex reduces
the tenocyte phenotype via reduction of Scx expression,
decreased cell turnover and decreased expression of colla-
gen 1, 3, 14 in primary tendon cells. This study suggests
that Dex may weaken the tendon structure in vivo.
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